These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30618037)

  • 1. Proteomic pattern of cervico-vaginal fluid (CVF) in an ovarian cancer diagnosis - pilot study.
    Gasiorowska E; Urbaniak B; Lorek J; Matysiak J; Nowak-Markwitz E
    Ginekol Pol; 2018; 89(12):688-694. PubMed ID: 30618037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
    Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
    J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
    Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
    BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
    Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
    Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic studies of early-stage and advanced ovarian cancer patients.
    Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
    Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic analysis of serum of women with elevated Ca-125 to differentiate malignant from benign ovarian tumors.
    Li L; Xu Y; Yu CX
    Asian Pac J Cancer Prev; 2012; 13(7):3265-70. PubMed ID: 22994745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution serum proteomic features for ovarian cancer detection.
    Conrads TP; Fusaro VA; Ross S; Johann D; Rajapakse V; Hitt BA; Steinberg SM; Kohn EC; Fishman DA; Whitely G; Barrett JC; Liotta LA; Petricoin EF; Veenstra TD
    Endocr Relat Cancer; 2004 Jun; 11(2):163-78. PubMed ID: 15163296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
    Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
    Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
    Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
    Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.
    Miao R; Badger TC; Groesch K; Diaz-Sylvester PL; Wilson T; Ghareeb A; Martin JA; Cregger M; Welge M; Bushell C; Auvil L; Zhu R; Brard L; Braundmeier-Fleming A
    PLoS One; 2020; 15(1):e0227707. PubMed ID: 31917801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
    Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
    Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buffalo cervico-vaginal fluid proteomics with special reference to estrous cycle: heat shock protein (HSP)-70 appears to be an estrus indicator.
    Muthukumar S; Rajkumar R; Karthikeyan K; Liao CC; Singh D; Akbarsha MA; Archunan G
    Biol Reprod; 2014 May; 90(5):97. PubMed ID: 24621924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
    Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
    Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
    Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
    Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
    Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
    Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive proteomic analysis of human cervical-vaginal fluid.
    Dasari S; Pereira L; Reddy AP; Michaels JE; Lu X; Jacob T; Thomas A; Rodland M; Roberts CT; Gravett MG; Nagalla SR
    J Proteome Res; 2007 Apr; 6(4):1258-68. PubMed ID: 17373839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: leveraging proteomics and machine learning for biomarker discovery.
    Njoku K; Pierce A; Chiasserini D; Geary B; Campbell AE; Kelsall J; Reed R; Geifman N; Whetton AD; Crosbie EJ
    EBioMedicine; 2024 Apr; 102():105064. PubMed ID: 38513301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
    Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
    Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.